120
Participants
Start Date
February 23, 2023
Primary Completion Date
August 12, 2023
Study Completion Date
August 13, 2023
Remimazolam
The patient receives continuous infusion of remimazolam at a rate of 0.3-1.0 mg/kg/hr.
Propofol
Patients are administered propofol at an effective site concentration of 1.0-2.5 mcg/ml through target-controlled infusion.
Dexmedetomidine
The patient is administered a dose of dexmedetomidine at 1 mcg/kg for 10 minutes, followed by continuous infusion at a rate of 0.2-1.0 mcg/kg/hr.
Asan Medical Center, Seoul
Lead Sponsor
Asan Medical Center
OTHER